Introduction of innovative products in the market and growing awareness about reproductive and sexual health in emerging regions are likely to drive the market in the coming years.
Intrauterine devices, injectable, vaginal rings, implants, pills, and patches are various methods used for hormonal contraception, which acts on the endocrine system to prevent ovulation.
Increasing number of women in developing economies are using contraceptives due to rise in government initiatives and programs, which is anticipated to accelerate market growth.
In the US, programs have been established to promote use of effective methods of contraception and to help women avoid pregnancies.
Increasing demand for contraceptive methods can be attributed to growing awareness about pills and devices, increasing significance of family planning, and supportive government regulations improving access to these products
The IUD segment is expected to witness the fastest growth during the forecast period. This can be attributed to entry of new devices in the market over the recent past, availability of long-acting reversible birth control methods, and more than 99.0% effectivity.
The Asia Pacific region is estimated to witness the fastest growth during the forecast period due to high unmet need, expected increase in coverage during the next 15 years, and increasing number of women of reproductive age.
Grand View Research provides syndicated research reports, customized research reports, and consulting services.
To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon